2017 Federally Facilitated Marketplaces: Implications for Pharmaceutical and Biotech Companies
•
2 likes•197 views
The Centers for Medicare & Medicaid Services released its 2017 guidance on the FFM and this PowerPoint highlights the most critical takeaway points for pharma and biotech manufacturers.
Report
Share
Report
Share
Download to read offline
Recommended
Cadth 2015 breakfast 3 5. j. mc phee seb panel public perspective
This document discusses the interest in biosimilars and their potential impact on drug plans. It notes that biologics make up 18% of provincial drug plan spending and costs are growing rapidly. Considerations for drug plans include improving patient care while reducing costs in line with the "Triple Aim" framework. Biosimilars may help address fiscal realities by managing budgets for growing plan memberships. Challenges include limited early evidence and health system costs, while opportunities include collaborations to generate real-world evidence and experience from other jurisdictions. Payers will use various approaches like listings, switching policies, and price negotiations to realize biosimilar savings.
How Prescription Drugs are Approved in Canada
This webinar provides insight into how the drug approval process affects what prescription drugs are available to patients in Canada. The presentation will cover the following topics: Who is responsible for prescription drug approval in Canada? How does the drug approval process impact patient access to medication? How can patients be involved in the drug approval process?
Pharmacare - Caveat Emptor (Let the Buyer Beware)
The document outlines a discussion on developing a universal pharmacare program in Canada, including reviewing different models proposed, lessons from international programs, and perspectives from mental health advocates. A vision and principles for a potential universal pharmacare plan are proposed that emphasize equitable access to necessary medications for all Canadians through a publicly-funded program. Next steps discussed include finalizing a report and seeking opportunities to promote the proposed approach.
Private Insurance Plans - Do they have a future in Canada?
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Background to the role of private drug insurance plans in Canada
● Impact on access of recent developments in private insurance plan programs
● Future directions of private insurance in Canada
View the video: https://youtu.be/rik50CrMffY
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Canadian Organization for Rare Disorders
This document summarizes Pamela Gavin's presentation on an evidence-based approach to assuring value for orphan drugs at the CEPHT Conference in Toronto. It discusses the progress made since the 1983 Orphan Drug Act, including over 700 approved orphan drugs. It then introduces the NORD-Trio partnership, which aims to ensure adequate access to orphan drugs through a patient-centric technology platform that measures stakeholder performance, defines quality measures, and advocates for patients and high performance. Finally, it provides examples of how this partnership could study the hepatitis C treatment landscape using real-world data on outcomes, access, and affordability.Examining Models for a National Pharmacare Program
Please share this slideshow with anyone who may be interested!
In this webinar:
● What has prompted the recent re-emergence of public calls for national pharmacare?
● What are Canadian health ministers doing to address this issue?
● What are some potential models for national pharmacare that are under discussion?
Contact the presenters:
● Bill Dempster - wdempster@3sixtypublicaffairs.com
● Gerry Jeffcott - gjeffcott@3sixtypublicaffairs.com
View the video: https://youtu.be/Eh3593x4aoI
How patient groups can have more say in the drug approval process
In this presentation, Bill Dempster and Johanne Chambers of 3Sixty Public Affairs walk through the different steps in bringing a new medicine through the regulatory review process, health technology assessment and funding, highlighting where patients can make a difference, and how their role is rapidly expanding.
The Cancer Medication Geographical Roulette in Canada
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on disparities in provincial reimbursement for cancer medications, and what patients can do about it
● Explanation of the different ways that cancer treatments are managed and funded across Canada, and outline the impact this has on patients depending on where they live in the country
View the video: https://youtu.be/NN3AcGYMXac
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Recommended
Cadth 2015 breakfast 3 5. j. mc phee seb panel public perspective
This document discusses the interest in biosimilars and their potential impact on drug plans. It notes that biologics make up 18% of provincial drug plan spending and costs are growing rapidly. Considerations for drug plans include improving patient care while reducing costs in line with the "Triple Aim" framework. Biosimilars may help address fiscal realities by managing budgets for growing plan memberships. Challenges include limited early evidence and health system costs, while opportunities include collaborations to generate real-world evidence and experience from other jurisdictions. Payers will use various approaches like listings, switching policies, and price negotiations to realize biosimilar savings.
How Prescription Drugs are Approved in Canada
This webinar provides insight into how the drug approval process affects what prescription drugs are available to patients in Canada. The presentation will cover the following topics: Who is responsible for prescription drug approval in Canada? How does the drug approval process impact patient access to medication? How can patients be involved in the drug approval process?
Pharmacare - Caveat Emptor (Let the Buyer Beware)
The document outlines a discussion on developing a universal pharmacare program in Canada, including reviewing different models proposed, lessons from international programs, and perspectives from mental health advocates. A vision and principles for a potential universal pharmacare plan are proposed that emphasize equitable access to necessary medications for all Canadians through a publicly-funded program. Next steps discussed include finalizing a report and seeking opportunities to promote the proposed approach.
Private Insurance Plans - Do they have a future in Canada?
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Background to the role of private drug insurance plans in Canada
● Impact on access of recent developments in private insurance plan programs
● Future directions of private insurance in Canada
View the video: https://youtu.be/rik50CrMffY
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Canadian Organization for Rare Disorders
This document summarizes Pamela Gavin's presentation on an evidence-based approach to assuring value for orphan drugs at the CEPHT Conference in Toronto. It discusses the progress made since the 1983 Orphan Drug Act, including over 700 approved orphan drugs. It then introduces the NORD-Trio partnership, which aims to ensure adequate access to orphan drugs through a patient-centric technology platform that measures stakeholder performance, defines quality measures, and advocates for patients and high performance. Finally, it provides examples of how this partnership could study the hepatitis C treatment landscape using real-world data on outcomes, access, and affordability.Examining Models for a National Pharmacare Program
Please share this slideshow with anyone who may be interested!
In this webinar:
● What has prompted the recent re-emergence of public calls for national pharmacare?
● What are Canadian health ministers doing to address this issue?
● What are some potential models for national pharmacare that are under discussion?
Contact the presenters:
● Bill Dempster - wdempster@3sixtypublicaffairs.com
● Gerry Jeffcott - gjeffcott@3sixtypublicaffairs.com
View the video: https://youtu.be/Eh3593x4aoI
How patient groups can have more say in the drug approval process
In this presentation, Bill Dempster and Johanne Chambers of 3Sixty Public Affairs walk through the different steps in bringing a new medicine through the regulatory review process, health technology assessment and funding, highlighting where patients can make a difference, and how their role is rapidly expanding.
The Cancer Medication Geographical Roulette in Canada
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on disparities in provincial reimbursement for cancer medications, and what patients can do about it
● Explanation of the different ways that cancer treatments are managed and funded across Canada, and outline the impact this has on patients depending on where they live in the country
View the video: https://youtu.be/NN3AcGYMXac
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationCanadian Cancer Survivor Network
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/SurvivornetcaWebinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients Canadian Cancer Survivor Network
At this webinar, Steve Sampson (Global Public Affairs) discusses how the upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money should always be the focus for government, but the need for cost-containment needs to be balanced with access to optimal healthcare innovation for patients.Access to Drugs for Rare Diseases in Canada - April 2014
The document discusses access to drugs for rare diseases in Canada. It notes that Canada currently has no orphan drug policy or definition of rare diseases, unlike the US and EU. As a result, Canadian patients have access to only about half of the orphan drugs approved in the US and EU. A new proposed Canadian orphan drug regulatory framework aims to align with international standards to promote drug development and patient access. It also discusses challenges for drug reimbursement in Canada given the high costs of rare disease drugs and limitations of current review processes. Lifecycle approaches and managed entry programs are proposed to help improve sustainable access.
Pharma funding of patient groups: the building blocks of ethical and appropri...
Pharma funding of patient groups: the building blocks of ethical and appropri...Canadian Cancer Survivor Network
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public AffairsManaging Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...Canadian Organization for Rare Disorders
This document discusses the challenges public payers face with expensive drugs for rare diseases. It outlines the formation of a working group between Alberta, British Columbia, and Ontario to explore evidence-based approaches. The working group identified major themes of communication, evidence, pricing, and access. Opportunities exist to improve communication with patients and clinicians, establish robust evidence standards, assess cost-effectiveness and affordability, and balance timely access with stakeholder accountability. The working group's goal is to develop sustainable, evidence-informed solutions that promote equity and transparency for rare disease patients.Calculating Member Cost Sharing for Pharmacy Claims
The document discusses challenges in calculating member pharmacy costs for health insurance plans. It describes how chronic conditions often require significant pharmacy utilization, but medications may not be covered by plans or may be on high-cost tiers. The Medicare Part D Plan Finder tool aims to help members find low-cost plans but has limitations. State health exchange data is available for some plans but may not provide full details needed. Calculating costs accurately is challenging due to issues like combined deductibles, drug pricing differences between pharmacies, and modeling non-formulary drugs.
Specialty one pager FINAL
This document discusses specialty drug management solutions from PwC. It notes that specialty drugs are the fastest growing component of pharmacy costs, accounting for 32% of costs while only representing 1% of prescriptions. There are concerns about the high and increasing costs of specialty drugs, variations in their management across pharmacy and medical benefits, and lack of transparency. PwC's approach involves diagnosing spending trends, formulating management strategies like innovative pricing and site of care optimization, and implementing programs to realize annual savings of 5-15% or $186,000-$558,000 for a typical employer.
Glenn Monteith expert patients forum
This presentation discusses innovative pathways to drug access in private drug coverage plans. It notes that many players are involved in private drug plans, including insurers, plan members, plan sponsors, advisors, insurance carriers, pharmacy benefit managers, and pharmacies. It also discusses some of the cost containment measures commonly used by private drug plans, such as generic substitution, tiered formularies, therapeutic substitution, prior authorization, and case management. In closing, it emphasizes getting to know your private drug plan and how plan design can impact access to medications, as well as noting the complexity of coordinating benefits between different plans.
Dr. Aaron Kesselheim: "Runaway Train: America’s Drug Price Problem"
Dr. Aaron Kesselheim's slides from the Center for Health Journalism webinar, "Runaway Train: America’s Drug Price Problem," 5.15.18
More info: https://www.centerforhealthjournalism.org/content/runaway-train-americas-drug-price-problem
David Mitchell: "Runaway Train: America’s Drug Price Problem"
David Mitchell's slides from the Center for Health Journalism webinar, "Runaway Train: America’s Drug Price Problem," 5.15.18
More info: https://www.centerforhealthjournalism.org/content/runaway-train-americas-drug-price-problem
CADTH - Why it is important, and what now?
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveCanadian Organization for Rare Disorders
Ontario has developed a framework to evaluate drugs for rare diseases (DRDs) since 2008, as these drugs often do not meet traditional standards for efficacy and cost-effectiveness. The framework uses all available evidence, including indirect evidence and evidence used for regulatory approval, to predict how a DRD may impact disease progression. It considers the natural progression of the disease and where the drug may provide treatment effects. Cost-effectiveness is not a consideration. A working group reviews DRDs and makes funding recommendations to the executive officer. Seven DRDs have been reviewed using this framework so far. The process can be exhaustive and time-consuming, but it has allowed Ontario to fund several important DRDs. Insufficient disease dataRare Disorders Policies in Canada: Who’s who and what’s what
Rare Disorders Policies in Canada: Who’s who and what’s whatCanadian Organization for Rare Disorders
The document summarizes rare disorders policies in Canada. It discusses the federal regulatory framework, which aims to accelerate access to orphan drugs through incentives like fee mitigation and accelerated review. However, Canada does not have market exclusivity for orphan drugs unlike other countries. It also discusses HTA in Canada, noting CADTH determined not to substantially change its processes for orphan drugs. Provincial funding models are challenging due to high drug costs. The document ends by briefly mentioning health system uptake, access programs, and research related to rare disorders policies.STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...Canadian Organization for Rare Disorders
A Rare International Dialogue (Saturday May 11, 2019)
Designing Pathways to Patient-Centered Care
Bone marrow as a Vehicle for Correction of Rare Disorders: Donna Wall, The Hospital for Sick Children Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
The document discusses Canada's orphan drug regulatory framework and opportunities to improve access to rare disease drugs across Canada. It advocates for a life-cycle approach and managed access schemes where drugs are approved with evidence collection requirements. Traditional health technology assessment limits orphan drug access by rejecting drugs that are not cost-effective based on small clinical trials. The document recommends performance-based managed access programs with national guidelines and risk-sharing between provinces, patients, and companies to improve access while collecting long-term evidence on benefits, harms, and costs.Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...Canadian Cancer Survivor Network
The document summarizes the federal parties' stances on health and oncology policy based on their responses to questions from the Canadian Cancer Survivor Network (CCSN). The Conservative Party had not yet provided any answers. The Liberal Party, NDP, and Bloc Quebecois provided responses supporting expanding employment insurance sickness benefits, improving access to disability benefits, and working with provinces on a national pharmacare program. The Liberal Party and NDP emphasized increasing healthcare funding and leadership. The Green Party had not yet responded.Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
This document summarizes information from PORTAL (Program On Regulation, Therapeutics, And Law) about prescription drug prices and value in the US. It notes that prescription drug spending has risen significantly in recent years due largely to high prices of brand name drugs. However, drug prices do not reflect true value, as the FDA approval process does not consider value, payors have limited ability to exclude low-value drugs, and physicians are not required to consider value when prescribing. Potential solutions discussed include value-based contracts, systematic assessment of drug value, and policy changes to promote value-based prescribing.RDD 2020 Day 1 PM: Health Canada Regulatory Update
Regulatory Update Panel
An overview of all Health Canada policies supporting access to Drugs for Rare Diseases, including regulatory pathways and support for innovation, patient engagement, Special Access Programs, aligned HC/CADTH/INESSS, international harmonization, post-market monitoring, support for patient registries, current status and relevance of biosimilars for rare disease patients
Rare Disease Day Conference 2020 March 9-10
Effective Global Site Budgeting and Cost Management - Holly Squires
Presentation delivered at "The State of Clinical Development Costs" conference in Philadelphia, PA January 11th and 12th, of 2011.
Refocus PMPRB “Back to the Future”: Part One.
August 19, 2021 from 1-2 pm
CORD’s LAST SUMMER webinar, Part 1 of our series on “How to Get Back to the PMPRB Original Mandate to prevent excessive drug pricing and support pharma R&D investment.” Learn why responding to the most recent (July 15th) proposed guideline changes is very important.
On August 19, 2021 from 1-2 pm, please JOIN:
Federal pharmaceutical pricing reform: What do patients think?
The document summarizes proposed changes to Canada's regulations for pricing patented medicines. It discusses:
- The role of the Patented Medicine Prices Review Board (PMPRB) in regulating drug prices.
- Proposed changes including adding new economic factors, updating comparator countries, and requiring reporting of discounts.
- Potential consequences like reduced drug launches in Canada, delays in drug availability, and price erosion over time.
- Questions around whether the changes will actually lower public drug prices significantly or risk reducing patient access to innovative therapies.
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Primer for attendees attending the November 15-16 Drug Pricing Policy Summit
● Broad conceptual blueprint of federal and provincial/territorial public health policy structures across Canada
● Description of legal frameworks, government responsibility centres and their mandates for treatment access, with reference to specific opportunities for patient engagement
View the video: https://youtu.be/X9AB70om-Dw
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
More Related Content
What's hot
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationCanadian Cancer Survivor Network
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/SurvivornetcaWebinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients Canadian Cancer Survivor Network
At this webinar, Steve Sampson (Global Public Affairs) discusses how the upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money should always be the focus for government, but the need for cost-containment needs to be balanced with access to optimal healthcare innovation for patients.Access to Drugs for Rare Diseases in Canada - April 2014
The document discusses access to drugs for rare diseases in Canada. It notes that Canada currently has no orphan drug policy or definition of rare diseases, unlike the US and EU. As a result, Canadian patients have access to only about half of the orphan drugs approved in the US and EU. A new proposed Canadian orphan drug regulatory framework aims to align with international standards to promote drug development and patient access. It also discusses challenges for drug reimbursement in Canada given the high costs of rare disease drugs and limitations of current review processes. Lifecycle approaches and managed entry programs are proposed to help improve sustainable access.
Pharma funding of patient groups: the building blocks of ethical and appropri...
Pharma funding of patient groups: the building blocks of ethical and appropri...Canadian Cancer Survivor Network
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public AffairsManaging Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...Canadian Organization for Rare Disorders
This document discusses the challenges public payers face with expensive drugs for rare diseases. It outlines the formation of a working group between Alberta, British Columbia, and Ontario to explore evidence-based approaches. The working group identified major themes of communication, evidence, pricing, and access. Opportunities exist to improve communication with patients and clinicians, establish robust evidence standards, assess cost-effectiveness and affordability, and balance timely access with stakeholder accountability. The working group's goal is to develop sustainable, evidence-informed solutions that promote equity and transparency for rare disease patients.Calculating Member Cost Sharing for Pharmacy Claims
The document discusses challenges in calculating member pharmacy costs for health insurance plans. It describes how chronic conditions often require significant pharmacy utilization, but medications may not be covered by plans or may be on high-cost tiers. The Medicare Part D Plan Finder tool aims to help members find low-cost plans but has limitations. State health exchange data is available for some plans but may not provide full details needed. Calculating costs accurately is challenging due to issues like combined deductibles, drug pricing differences between pharmacies, and modeling non-formulary drugs.
Specialty one pager FINAL
This document discusses specialty drug management solutions from PwC. It notes that specialty drugs are the fastest growing component of pharmacy costs, accounting for 32% of costs while only representing 1% of prescriptions. There are concerns about the high and increasing costs of specialty drugs, variations in their management across pharmacy and medical benefits, and lack of transparency. PwC's approach involves diagnosing spending trends, formulating management strategies like innovative pricing and site of care optimization, and implementing programs to realize annual savings of 5-15% or $186,000-$558,000 for a typical employer.
Glenn Monteith expert patients forum
This presentation discusses innovative pathways to drug access in private drug coverage plans. It notes that many players are involved in private drug plans, including insurers, plan members, plan sponsors, advisors, insurance carriers, pharmacy benefit managers, and pharmacies. It also discusses some of the cost containment measures commonly used by private drug plans, such as generic substitution, tiered formularies, therapeutic substitution, prior authorization, and case management. In closing, it emphasizes getting to know your private drug plan and how plan design can impact access to medications, as well as noting the complexity of coordinating benefits between different plans.
Dr. Aaron Kesselheim: "Runaway Train: America’s Drug Price Problem"
Dr. Aaron Kesselheim's slides from the Center for Health Journalism webinar, "Runaway Train: America’s Drug Price Problem," 5.15.18
More info: https://www.centerforhealthjournalism.org/content/runaway-train-americas-drug-price-problem
David Mitchell: "Runaway Train: America’s Drug Price Problem"
David Mitchell's slides from the Center for Health Journalism webinar, "Runaway Train: America’s Drug Price Problem," 5.15.18
More info: https://www.centerforhealthjournalism.org/content/runaway-train-americas-drug-price-problem
CADTH - Why it is important, and what now?
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveCanadian Organization for Rare Disorders
Ontario has developed a framework to evaluate drugs for rare diseases (DRDs) since 2008, as these drugs often do not meet traditional standards for efficacy and cost-effectiveness. The framework uses all available evidence, including indirect evidence and evidence used for regulatory approval, to predict how a DRD may impact disease progression. It considers the natural progression of the disease and where the drug may provide treatment effects. Cost-effectiveness is not a consideration. A working group reviews DRDs and makes funding recommendations to the executive officer. Seven DRDs have been reviewed using this framework so far. The process can be exhaustive and time-consuming, but it has allowed Ontario to fund several important DRDs. Insufficient disease dataRare Disorders Policies in Canada: Who’s who and what’s what
Rare Disorders Policies in Canada: Who’s who and what’s whatCanadian Organization for Rare Disorders
The document summarizes rare disorders policies in Canada. It discusses the federal regulatory framework, which aims to accelerate access to orphan drugs through incentives like fee mitigation and accelerated review. However, Canada does not have market exclusivity for orphan drugs unlike other countries. It also discusses HTA in Canada, noting CADTH determined not to substantially change its processes for orphan drugs. Provincial funding models are challenging due to high drug costs. The document ends by briefly mentioning health system uptake, access programs, and research related to rare disorders policies.STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...Canadian Organization for Rare Disorders
A Rare International Dialogue (Saturday May 11, 2019)
Designing Pathways to Patient-Centered Care
Bone marrow as a Vehicle for Correction of Rare Disorders: Donna Wall, The Hospital for Sick Children Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
The document discusses Canada's orphan drug regulatory framework and opportunities to improve access to rare disease drugs across Canada. It advocates for a life-cycle approach and managed access schemes where drugs are approved with evidence collection requirements. Traditional health technology assessment limits orphan drug access by rejecting drugs that are not cost-effective based on small clinical trials. The document recommends performance-based managed access programs with national guidelines and risk-sharing between provinces, patients, and companies to improve access while collecting long-term evidence on benefits, harms, and costs.Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...Canadian Cancer Survivor Network
The document summarizes the federal parties' stances on health and oncology policy based on their responses to questions from the Canadian Cancer Survivor Network (CCSN). The Conservative Party had not yet provided any answers. The Liberal Party, NDP, and Bloc Quebecois provided responses supporting expanding employment insurance sickness benefits, improving access to disability benefits, and working with provinces on a national pharmacare program. The Liberal Party and NDP emphasized increasing healthcare funding and leadership. The Green Party had not yet responded.Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
This document summarizes information from PORTAL (Program On Regulation, Therapeutics, And Law) about prescription drug prices and value in the US. It notes that prescription drug spending has risen significantly in recent years due largely to high prices of brand name drugs. However, drug prices do not reflect true value, as the FDA approval process does not consider value, payors have limited ability to exclude low-value drugs, and physicians are not required to consider value when prescribing. Potential solutions discussed include value-based contracts, systematic assessment of drug value, and policy changes to promote value-based prescribing.RDD 2020 Day 1 PM: Health Canada Regulatory Update
Regulatory Update Panel
An overview of all Health Canada policies supporting access to Drugs for Rare Diseases, including regulatory pathways and support for innovation, patient engagement, Special Access Programs, aligned HC/CADTH/INESSS, international harmonization, post-market monitoring, support for patient registries, current status and relevance of biosimilars for rare disease patients
Rare Disease Day Conference 2020 March 9-10
Effective Global Site Budgeting and Cost Management - Holly Squires
Presentation delivered at "The State of Clinical Development Costs" conference in Philadelphia, PA January 11th and 12th, of 2011.
Refocus PMPRB “Back to the Future”: Part One.
August 19, 2021 from 1-2 pm
CORD’s LAST SUMMER webinar, Part 1 of our series on “How to Get Back to the PMPRB Original Mandate to prevent excessive drug pricing and support pharma R&D investment.” Learn why responding to the most recent (July 15th) proposed guideline changes is very important.
On August 19, 2021 from 1-2 pm, please JOIN:
What's hot (20)
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and Innovation
Webinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients
Access to Drugs for Rare Diseases in Canada - April 2014
Access to Drugs for Rare Diseases in Canada - April 2014
Pharma funding of patient groups: the building blocks of ethical and appropri...
Pharma funding of patient groups: the building blocks of ethical and appropri...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Calculating Member Cost Sharing for Pharmacy Claims
Calculating Member Cost Sharing for Pharmacy Claims
Dr. Aaron Kesselheim: "Runaway Train: America’s Drug Price Problem"
Dr. Aaron Kesselheim: "Runaway Train: America’s Drug Price Problem"
David Mitchell: "Runaway Train: America’s Drug Price Problem"
David Mitchell: "Runaway Train: America’s Drug Price Problem"
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program Perspective
Rare Disorders Policies in Canada: Who’s who and what’s what
Rare Disorders Policies in Canada: Who’s who and what’s what
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Federal Election Special - What are the Parties Saying About Healthcare and C...
Federal Election Special - What are the Parties Saying About Healthcare and C...
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
Aaron S. Kesselheim, Prescription Drug Prices and "Value"
RDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory Update
Effective Global Site Budgeting and Cost Management - Holly Squires
Effective Global Site Budgeting and Cost Management - Holly Squires
Similar to 2017 Federally Facilitated Marketplaces: Implications for Pharmaceutical and Biotech Companies
Federal pharmaceutical pricing reform: What do patients think?
The document summarizes proposed changes to Canada's regulations for pricing patented medicines. It discusses:
- The role of the Patented Medicine Prices Review Board (PMPRB) in regulating drug prices.
- Proposed changes including adding new economic factors, updating comparator countries, and requiring reporting of discounts.
- Potential consequences like reduced drug launches in Canada, delays in drug availability, and price erosion over time.
- Questions around whether the changes will actually lower public drug prices significantly or risk reducing patient access to innovative therapies.
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Primer for attendees attending the November 15-16 Drug Pricing Policy Summit
● Broad conceptual blueprint of federal and provincial/territorial public health policy structures across Canada
● Description of legal frameworks, government responsibility centres and their mandates for treatment access, with reference to specific opportunities for patient engagement
View the video: https://youtu.be/X9AB70om-Dw
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...
In 2016, spending on prescription drugs is expected to reach $500 billion. So, how high will they really go? That is a common question asked with drug prices as recent headlines have exploited drug pricing schemes and how the pharmaceutical industry is handling rising prices. This webinar discusses how hospitals and health systems can prepare for and manage rising drug costs, ensure patient care and positively impact the bottom line.
The Mad, Fairytale World of Drug Approval in Canada
Gerry Jeffcott, of 360 Public Affairs, gave a presentation for the CCSN on the drug approval process in Canada on March 27, 2014. He outlines the divide between public and private networks, cost management, as well as the review and approval process for pharmaceuticals in Canada.
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...Canadian Organization for Rare Disorders
Summer 2020 PMPRB Webinar Series: Webinar 2 (July 16, 2020)
Hearing From Those Who Really Matter. This Webinar will take place after the PMPRB’s promised rescheduled “public forums” and “research webinars.”
Roundtable
Lindy Forte, Principal Consultant, Patient Access Solutions
Dr. Shawn Whatley, family physician, Munk Senior Fellow, Macdonald Laurier Institute and past president of the OMA
Barbara Jaszewski, Advisor Cloud and past global vice president of pricing and market access
Catherine Boivin, SMA Patient
Durhane Wong-Rieger, President & CEO, CORD
Moderator: Bill Dempster, CEO, 3Sixty Public Affairs
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...
The document discusses the rise of pharmaceutical comparative effectiveness research (CER) in the United States. CER provides insight into the clinical and cost effectiveness of different drug therapies. It is being driven by growing government and private payer interest in justifying healthcare costs. The federal government is a major funder of CER through agencies like AHRQ and NIH. For pharmaceutical companies, demonstrating strong CER performance can help gain preferred formulary placement and market position, while poor performance may disadvantage a drug. The document outlines considerations for a pharmaceutical brand to conduct its own pilot CER study to evaluate its drug against competitors.
Health Technology Assessment: Comparison between UK and Canada Processes by D...
The document compares the health technology assessment (HTA) processes in the UK and Canada. Both countries have national HTA agencies that evaluate new health technologies. The UK's agency is NICE, while Canada's is CADTH. They share principles like considering clinical efficacy, cost-effectiveness, and patient input. However, their processes differ in that NICE recommendations must be followed, while CADTH's are non-binding. Overall, the UK and Canada demonstrate similarities in HTA aims but differences in implementation and impact due to unique healthcare systems and policy environments.
Access to cancer drugs under pharmacare
The document outlines an ideal vision for a universal Pharmacare program in Canada with the following key elements: all Canadians would have prescription drug coverage through a national formulary with no copays or deductibles; all Health Canada approved drugs would be reimbursed; and the process for reviewing drugs' clinical effectiveness would be fully transparent. However, it also notes some challenges with implementing this vision, including uncertainty around timely access to new drugs given the lengthy review process, the need to account for provincial healthcare priorities in a national formulary, and insufficient public funding requiring alternative sources and mechanisms to ensure access to necessary medications like cancer drugs.
Doug Clark, PMPRB Jan 31, 2018 How to Ensure Patient-Centred Pharmacare is Co...
Doug Clark, PMPRB Jan 31, 2018 How to Ensure Patient-Centred Pharmacare is Co...Canadian Organization for Rare Disorders
Jan 31, 2018 How to Ensure Patient-Centred Pharmacare is Cost-Effective Healthcare
A Consultation on Patented Medicine Prices Review Board & Biologic Medicines
Why Pharmaceutical Prices are Rising and How We Can Fight Against Them?
Pharmaceutical prices are rising due to minimal government regulation, lack of competition, end of generic drugs wave, supply disruptions and industry consolidation. This leads to increased healthcare costs, formulary changes, nonadherence and rationing of medications. Possible solutions include increasing price transparency, competition, importing drugs from other countries, and legislation prohibiting pay-for-delay deals. Harris Health implemented cost control strategies like a closed formulary, therapeutic substitutions, and patient assistance programs, achieving over $60 million in savings and cost avoidance in fiscal year 2016.
Innovating and Advocating for Community Cancer Care
This document summarizes key issues in oncology care policy in the United States. It discusses the changing political environment under the new administration, ongoing payment reform efforts including the Oncology Care Model, issues around rising drug prices and pharmacy benefit managers, and the uncertain future of repealing and replacing the Affordable Care Act. The consolidation of cancer care and its impact on community oncology practices is also addressed.
RDD 2020 Day 2 AM: Wayne Critchley
Wayne Critchley, Global Public Affairs: PMPRB Reform and Patient Access to Drugs for Rare Diseases
Rare Disease Day 2020 Conference March 10, 2020
HawkPartners Perspective on Payer Research
If done right, payer research can offer important insights for your enterprise.
To learn more about HawkPartners, visit hawkpartners.com
Aaron S. Kesselheim, "Drug Pricing"
Aaron S. Kesselheim, "Drug Pricing"The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
December 12, 2017
The Sixth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2017 and what to watch out for in 2018. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/sixth-annual-health-law-year-in-p-reviewPharmaCon IIR Presentation 2013
Exploring medical aid member behaviour in a Single Exit Price (SEP) and Designated Service Provider (DSP) environment
Best Practices in Controlling Prescription Drug Costs
An insightful pharmacy benefit cost containment overview co-presented by Jeff Legg, PSG's Consulting Services VP and Labor Practice Leader, at the 2016 IFEBP Conference in Orlando.
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
Presented at “Financial Protection and Improved Access to Health Care: Peer-to-Peer Learning Workshop Finding Solutions to Common Challenges” in Accra, Ghana, February 2016. To learn more, visit: https://www.hfgproject.org/ghana-uhc-workshop
Pharmacoeconomics
Pharmacoeconomics is a branch of health economics that compares the value of one drug or therapy to another. It considers the inputs like drug costs as well as the outcomes and consequences of treatment. Pharmacoeconomic analyses help inform decisions about drug formularies, prescribing, and individual patient treatment by evaluating costs and effects. Common types of analyses include cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis, and cost-utility analysis. While useful for decision making, pharmacoeconomic evaluations also have limitations like lack of data and direct comparator studies.
Former government proposed models
The document outlines several past and proposed models for a national pharmacare program in Canada, including:
1. The 2003 First Ministers Health Accord and National Pharmaceuticals Strategy proposed universal coverage with two options for income-based cost sharing thresholds but negotiations failed.
2. The 2002 Kirby and Romanow reports recommended a $1500 annual catastrophic drug coverage threshold but their recommendations did not move forward.
3. The 2009 Canadian Treatment Action Council model proposed a universal catastrophic drug plan with income-based cost sharing, centralized management, and funding from governments, employers, and manufacturers.
The Prescription Drug Price Crisis
The document discusses the prescription drug price crisis in the United States. Drug prices have risen much faster than general inflation over the past decade, and millions of Americans cannot afford necessary medications as a result. The U.S. pays significantly higher prices for many drugs than other countries. Several policy solutions are proposed to lower drug costs, including allowing Medicare to negotiate drug prices, banning "pay-for-delay" deals between drug companies, and legalizing importation of lower-cost drugs from abroad. Advocacy groups are calling for stronger political action to enact reforms and lower what Americans pay for prescription medications.
Similar to 2017 Federally Facilitated Marketplaces: Implications for Pharmaceutical and Biotech Companies (20)
Federal pharmaceutical pricing reform: What do patients think?
Federal pharmaceutical pricing reform: What do patients think?
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...
The Mad, Fairytale World of Drug Approval in Canada
The Mad, Fairytale World of Drug Approval in Canada
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Doug Clark, PMPRB Jan 31, 2018 How to Ensure Patient-Centred Pharmacare is Co...
Doug Clark, PMPRB Jan 31, 2018 How to Ensure Patient-Centred Pharmacare is Co...
Why Pharmaceutical Prices are Rising and How We Can Fight Against Them?
Why Pharmaceutical Prices are Rising and How We Can Fight Against Them?
Innovating and Advocating for Community Cancer Care
Innovating and Advocating for Community Cancer Care
Best Practices in Controlling Prescription Drug Costs
Best Practices in Controlling Prescription Drug Costs
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
Financial Protection and Improved Access to Health Care: A Spotlight on Pharm...
Recently uploaded
CCSN_June_06 2024_jones. Cancer Rehabpptx
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Professional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine Lecture , Medical jurisprudence
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Unlocking the Secrets to Safe Patient Handling.pdf
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
Hypotension and role of physiotherapy in it
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
Can Allopathy and Homeopathy Be Used Together in India.pdf
This article explores the potential for combining allopathy and homeopathy in India, examining the benefits, challenges, and the emerging field of integrative medicine.
Top massage center in ajman chandrima Spa
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Hypertension and it's role of physiotherapy in it.
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
Pediatric Emergency Care for Children | Apollo Hospital
Pediatric Emergency Care for Children | Apollo HospitalApollo 24/7 Adult & Paediatric Emergency Services
At Apollo Hospital, Lucknow, U.P., we provide specialized care for children experiencing dehydration and other symptoms. We also offer NICU & PICU Ambulance Facility Services. Consult our expert today for the best pediatric emergency care.
For More Details:
Map: https://cutt.ly/BwCeflYo
Name: Apollo Hospital
Address: Singar Nagar, LDA Colony, Lucknow, Uttar Pradesh 226012
Phone: 08429021957
Opening Hours: 24X7Luxurious Spa In Ajman Chandrima Massage Center
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样
原版纸张【微信：741003700 】【(wsu毕业证书)美国华盛顿州立大学毕业证、学位证书】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
This edition features a handful of Champions of Health: Spotlight On Leaders Shaping Germany's Healthcare that are leading us into a better future.
Trauma Outpatient Center .
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
PET CT beginners Guide covers some of the underrepresented topics in PET CT
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Recently uploaded (20)
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Unlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdf
Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.
Pediatric Emergency Care for Children | Apollo Hospital
Pediatric Emergency Care for Children | Apollo Hospital
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
PET CT beginners Guide covers some of the underrepresented topics in PET CT
PET CT beginners Guide covers some of the underrepresented topics in PET CT
2017 Federally Facilitated Marketplaces: Implications for Pharmaceutical and Biotech Companies
- 1. By Amy DemskeBy Amy Demske 2017 Federally Facilitated Marketplaces: Implications for Pharmaceutical and Biotech Companies Presentation by Amy Demske
- 2. By Amy Demske Overview of Federally Facilitated Marketplaces (FFM) • 2017 Draft FFM Guidance Largely Mirrors 2016 Parameters • Expands Clinical Appropriateness Review to 9 High Cost, Chronic Conditions • Requires Issuers to Accept Premium and Cost-Sharing from Federal, State and Local Government Programs,By Amy DemskeFederal, State and Local Government Programs, Subgrantees and Downstream Entities (e.g. PBMs) • Proposes Reviews of: Outlier Thresholds Drug Coverage Cost-Sharing Formulary and Adverse Tiering
- 3. CMS Proposes 9 Chronic, High Cost Conditions for Review • Bipolar Disorder • Breast Cancer • Diabetes • Hepatitis C • HIV Drug Regimens Tier Placement/ Adverse Tiering• HIV • Multiple Sclerosis • Prostate Cancer • Rheumatoid Arthritis • Schizophrenia Formulary Outliers Adverse Tiering Cost-Sharing
- 4. CMS to Review QHP Drug Formularies Outlier Analysis Drug Coverage • Review of State and National Outlier Threshold Values • Requires a QHP to Meet/Exceed Both Standards • Review of QHP Coverage of Drugs for Bipolar Disorder, Diabetes, HIV, Rheumatoid Arthritis and Schizophrenia • Coverage of Standard Treatment Protocols (First, Second Line Therapies) and Step Therapy • Review QHPs with Unusually Large Numbers of Drugs Formulary/ Adverse Tiering Cost-Sharing • CMS will Identify Plans Looking for Unusually High Estimated Out-of-Pocket Costs As Compared to Similar Plans at State and National Level. • Review QHPs with Unusually Large Numbers of Drugs Subject to Prior Authorization • Evaluate Whether QHP Drug Coverage for Chronic, High- Cost Conditions is Consistently Assigned to High-Cost Tiers
- 5. Additional Considerations: ● CMS Proposes an Optional Lower-Cost Drug Tier for QHPs – Beyond 4 Standard Tiers Clinicians Should Consider Whether Therapies are Evidence-Based, and not Simply Cost-Based ● QHP’s are Required to Publish its Formulary Drug List on Healthcare.gov Drug Lists and Tiering must be Fully Transparent to Enrollees ● Non Discrimination Requirements of Essential Health Benefits are Largely the Responsibility of State Regulators The Decision-making Process must Ensure the Appropriate Therapy at the Right Time